市場調查報告書
商品編碼
1368659
下游加工市場規模 - 按技術、按產品(色譜柱、樹脂、過濾器)、按應用(單株抗體、疫苗)、最終用戶和預測,2023-2032 年Downstream Processing Market Size - By Technique, By Product (Chromatography Columns, Resins, Filters), By Application (Monoclonal Antibody, Vaccine), End-user & Forecast, 2023-2032 |
由於慢性病盛行率不斷上升,加上人口老化不斷加劇,下游加工市場規模預計2023年至2032年年複合成長率為10.5%。根據美國國立衛生研究院的數據,到2050年,99.5%的50歲以上人口將患有至少一種慢性病。 2020年,超過7,100萬人患有至少一種慢性病,預計到2050年這數字將超過1.42億人。
隨著擴大採用單株抗體和重組蛋白來治療這些慢性疾病,對生物製藥產品的需求持續激增。這一因素以及下游加工方法的技術發展和創新正在推動市場成長軌跡。
下游加工市場根據技術、產品、應用、最終用戶和地區分類。
預計從 2023 年到 2032 年,固液分離領域的年複合成長率將達到 11.2%。離心、過濾和色譜等技術因其能夠有效地從複雜混合物中分離生物分子而受到重視。這些技術的不斷改進增強了純化工藝,從而生產出高品質的生物製藥產品。創新分離技術的整合降低了生產成本,使這些技術越來越適用於各種下游加工應用。
由於採用了先進的過濾技術,包括微濾、超濾和奈米濾,過濾器領域預計 2023 年和 2032 年年複合成長率將達到 11.6%。這些過程最大限度地降低了污染風險。開發能夠去除雜質並保持精細生物分子完整性的高性能過濾器對於滿足嚴格的監管要求並確保生物製藥行業的產品安全性和有效性至關重要。
受醫療保健基礎設施投資增加、生物製藥製造業不斷成長以及研發活動不斷增加等因素的推動,亞太地區下游加工市場規模預計在 2023 年至 2032 年期間年複合成長率將接近 11%。中國、印度和日本等國家的生物技術和製藥產業正在取得巨大進步,導致對下游加工解決方案的需求激增。龐大的患者群體和對個人化醫療的日益關注進一步推動了該地區的市場成長。
Downstream processing market size is expected to 10.5% CAGR from 2023 to 2032 owing to the increasing prevalence of chronic diseases, coupled with a growing aging population. According to the National Institutes of Health, by 2050, 99.5% of the population above the age of 50 years or older will have at least one chronic disease. In 2020, more than 71 million people had at least one chronic disease which is expected to reach more than 142 million by 2050.
The demand for biopharmaceutical products continues to surge with the rising adoption of monoclonal antibodies and recombinant proteins for treating these chronic diseases. This factor, along with the technological developments and innovations in downstream processing methodologies are contributing to the market growth trajectory.
The downstream processing market is divided based on technique, product, application, end-user, and region.
The solid-liquid separation segment is predicted to record 11.2% CAGR from 2023 to 2032. Techniques like centrifugation, filtration, and chromatography have gained prominence due to their ability to efficiently separate biomolecules from complex mixtures. Continuous improvements in these techniques have led to enhanced purification processes, resulting in the production of high-quality biopharmaceutical products. The integration of innovative separation technologies has reduced production costs, making these techniques increasingly viable for various downstream processing applications.
The filters segment is anticipated to observe 11.6% CAGR during 2023 and 2032 owing to the adoption of advanced filtration technologies, including microfiltration, ultrafiltration, and nanofiltration. These processes have minimized the risk of contamination. The development of high-performance filters capable of removing impurities and preserving the integrity of delicate biomolecules has become crucial in meeting stringent regulatory requirements and ensuring product safety and efficacy in the biopharmaceutical industry.
Asia Pacific downstream processing market size is expected to observe nearly 11% CAGR between 2023 and 2032, driven by factors such as increasing investments in healthcare infrastructure, a growing biopharmaceutical manufacturing sector, and rising R&D activities. Countries like China, India, and Japan are witnessing substantial advancements in biotechnology and pharmaceutical industries, leading to a surge in demand for downstream processing solutions. The presence of a large patient pool and the escalating focus on personalized medicine are further propelling the market growth in the region.